Also categorized in BoardMoves:
What Lies Ahead For Chesapeake As McClendon Exits?
x hide permanently

Valeant Names ValueAct's Ubben to Board effective Oct. 1

Sept 25 (Reuters) - Valeant Pharmaceuticals International Inc said on Thursday it had named the head of a top shareholder, ValueAct Capital, to its board of directors and vowed to continue with its hostile takeover attempt on Botox maker Allergan Inc...

Mentions: Management hostile takeover Board of Directors